Metformin to Reduce Heart Failure After Myocardial Infarction

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will evaluate the effect of metformin therapy during 4 months in non-diabetic patients following ST-elevation myocardial infarction on left ventricular ejection fraction as measured with cardiac magnetic resonance imaging, compared to placebo.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Center Groningen
• Collaborator: ZonMw: The Netherlands Organisation for Health Research and Development
• Treatments: Metformin

Criteria

Inclusion Criteria:

• The diagnosis acute MI defined by chest pain suggestive for myocardial ischemia for at least 30 minutes, the time from onset of the symptoms less than 12 hours before hospital admission, and an ECG recording with ST- segment elevation of more than 0.1 mV in 2 or more leads.

• Successful primary PCI (post-procedural TIMI 2/3);

• At least one stent sized ≥ 3.0 mm;

• Eligible for 3T CMR imaging;

• Verbal followed by written informed consent.

Exclusion Criteria:

• rescue PCI after thrombolytic therapy;

• need for emergency coronary artery bypass grafting;

• creatinin >177 μmol/L measured pre-PCI;

• Younger than 18 years;

• Mechanical ventilation;

• Diabetes;

• Prior myocardial infarction;

• Contra-indication to metformin (see safety);

• The existence of a life-threatening disease with a life-expectancy of less than 6 months.